FIELD: medicine.
SUBSTANCE: method involves conducting blood analysis and determining a mitochondrial fluorescence both in an initial state, and after adding a blood sample with an examined in vitro metabolic corrector in a dose equal to a recommended single dose, and calculating fluorescence gain rates. If the mitochondrial fluorescence gain rate under the action of the metabolic corrector is >0, the mitochondria are considered activated under the action of the metabolic corrector in a specific patient, whereas the derived gain rate of <0 enables to state the depressed mitochondrial function under the action of the metabolic corrector in a specific patient.
EFFECT: presented method enables to determine the patient's individual sensitivity to a specific metabolic corrector for the purpose of the individual selection of a medicinal product and further effective treatment of the patients suffering from ischemic heart disease.
1 ex, 5 dwg
Title | Year | Author | Number |
---|---|---|---|
PLANT-DERIVED AGENT WITH CARDIOTONIC ACTIVITY IN CHRONIC HEART FAILURE | 2017 |
|
RU2654706C1 |
METHOD FOR CORRECTION OF LIPID PEROXIDATION PROCESSES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION | 2016 |
|
RU2627458C1 |
METHOD OF TREATING PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ON BACKGROUND OF METABOLIC SYNDROME | 2015 |
|
RU2595815C1 |
METHOD FOR DETERMINING THE ENERGY METABOLISM ENZYME DYSFUNCTION IN RESPIRATORY PATHOLOGY IN CHILDREN AND APPLICATION THEREOF | 2020 |
|
RU2759652C1 |
METHOD FOR DETERMINING SPECIFIC HYPERSENSITIVITY AND ITS NATURE in vitro | 2005 |
|
RU2295726C2 |
METHOD FOR DETERMINING SENSITIVITY TO IMMUNOMODULATIONS | 0 |
|
SU1777078A1 |
METHOD OF DETERMINING INDIVIDUAL HUMAN BLOOD LEUKOCYTE DRUG SENSITIVITY | 2009 |
|
RU2423705C2 |
METHOD OF PREDICTING COURSE OF MYOCARDIAL INFARCTION BASING ON ASSESSMENT OF MITOCHONDRIAL DYSFUNCTION EXPRESSION | 2011 |
|
RU2519700C2 |
METHOD OF TREATING NON-ALCOHOLIC LIVER DISEASE ACCOMPANYING TYPE 2 DIABETES MELLITUS | 2013 |
|
RU2538221C1 |
HEPATOPROTECTOR FOR TREATING NON-ALCOHOLIC LIVER DISEASE IN TYPE 2 DIABETES MELLITUS | 2013 |
|
RU2537227C1 |
Authors
Dates
2016-03-27—Published
2014-09-04—Filed